Alterações dermatológicas em pacientes oncológicos – adultos e crianças

Barra lateral de artigos

PDF
Publicado: ago 14, 2009
DOI: https://doi.org/10.7322/abcs.v34i2.132
Palavras-chave:
Efeitos adversos, neoplasia, radioterapia, quimioterapia

Conteúdo do artigo principal

Dolores Gonzalez Fabra
Disciplina de Dermatologia da Faculdade de Medicina do ABC (FMABC), Santo André (SP), Brasil.
Ana Paula Kayo
Departamento de Clínica Médica da FMABC, Santo André (SP), Brasil.
Andrea Regina de Oliveira Leal
Disciplina de Dermatologia da Faculdade de Medicina do ABC (FMABC), Santo André (SP), Brasil.
Vanessa Salzano
Departamento de Dermatologia do Hospital Infantil Darcy Vargas, São Paulo (SP), Brasil.
Flávia Guglielmino
Departamento de Clínica Médica da FMABC, Santo André (SP), Brasil.

Resumo

O tratamento oncológico, seja cirúrgico e/ou quimioterápico e/ou radioterápico, acarreta inúmeros efeitos adversos cutâneos – muitos deles já relatados na literatura. Por meio do Ambulatório de Reabilitação Dermato-Cosmiátrica da Faculdade de Medicina do ABC, pudemos catalogar as alterações dermatológicas e cosmiátricas decorrentes do tratamento oncológico, além de tratá-las durante a vigência do tratamento, sem interferir em seus resultados. O objetivo deste trabalho foi dividir as alterações dermatológicas e cosmiátricas decorrentes do tratamento oncológico em três grandes grupos: alterações desencadeadas, agravadas e não relacionadas ao tratamento oncológico – classificação esta ainda inédita na literatura médica. Além disso, o trabalho classificou as alterações de acordo com o tratamento oncológico realizado.

Detalhes do artigo

Edição
v. 34 n. 2 (2009)
Seção
Artigos Originais

Referências

Piérard-Frachimont C, Piérard GE. Comment j'explore… une perte de cheveux chez un patient cancéreux. Rev Med Liege 2004;59(9):525-9.

Hinds G, Thomas VD. Malignancy and cancer treatment-related hair and nail changes. Dermatol Clin 2008;26(1):59-68. http://dx.doi.org/10.1016/j.det.2007.08.003

Bursztejn AC, Tréchot P, Cuny JF, Schmutz JL, Barbaud A. Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplasic drus. Contact Dermatitis 2008;58(6):365-8. http://dx.doi.org/10.1111/j.1600-0536.2007.01285.x

Alley E, Green R, Schulter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002;14(2):212-6. http://dx.doi.org/10.1097/00001622-200203000-00012

Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006;33(1):86-97. http://dx.doi.org/10.1053/j.seminoncol.2005.11.004

Mori O, Matsuo K, Hashimoto T. Anticancer drugs induce apoptosis in mouse hair follicles. Kurume Med 2000;47(3):193-7. http://dx.doi.org/10.2739/kurumemedj.47.193

Chun YS, Chang SN, Oh D, Park WH. A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation. J Am Acad Dermatol 2000;43(2 Pt 2):358-60. http://dx.doi.org/10.1067/mjd.2000.101589

Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 2001;321(5):327-35. http://dx.doi.org/10.1097/00000441-200105000-00005

Mays SR, Cohen PR. Emerging dermatologic issues in the oncology patient. Semin Cutan Med Surg 2006;25(4):179-89. http://dx.doi.org/10.1016/j.sder.2006.08.007

Rupprecht R, Lippold A, Auras C, Bramkamp G, Breitkopf C, Elsmann HJ et al. Late side-effects with cosmetic relevance following soft X-ray therapy of cutaneous neoplasias. J Eur Acad Dermatol Venereol 2007;21(2):178-85. http://dx.doi.org/10.1111/j.1468-3083.2006.01886.x

Pezzano M, Duterque M, Lardoux H, Louvard Y, Morice MC, Lefèvre T et al. Radiodermite thoracique en cardiologie interventionnelle. A propos de 6 cas. Arch Mal Couer Vaiss 1999;92(9):1197-204.

Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park) 2006;20(5 Suppl 2):26-34.

Pai GS, Vilama AM, Dinesh M. Occurrence and severity of alopecia in patients on combination chemotherapy. Indian J Cancer 2000;37(2-3):95-104.

Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/IV receptor tyrosine kinase inhibitor. Arch Dermatol 2006;142(11):1477-9. http://dx.doi.org/10.1001/archderm.142.11.1477

Bleiker TO, Nicolaou N, Traulsen J, Hutchinson PE. 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans. Br J Dermatol 2005;153(1):103-12. http://dx.doi.org/10.1111/j.1365-2133.2005.06608.x

Dorr VJ. A practitioner's guide to cancer-related alopecia. Semin Oncol 1998;25(5):562-70.

Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004;208(1):49-54. http://dx.doi.org/10.1159/000075046

Chiewchanvit S, Noppakun K, Kanchanarattanakon K. Mucocutaneous complications of chemotherapy in 74 patients from Maharaj Nakorn Chiang Mai Hospital. J Med Assoc Thai 2004;87(5):508-14.

Lacouture ME, Boerner SA, Lorusso PM. Non-rash skin toxicities associated with targeted therapies. Clin Lung Cancer 2006;8 Suppl 1:S36-42. http://dx.doi.org/10.3816/CLC.2006.s.012

Ghetti E, Piraccini BM, Tosti A. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatol Venereol 2003;17(4):459-60. http://dx.doi.org/10.1046/j.1468-3083.2003.00774.x

Mackay-Wiggan J, Nair KG, Halasz CL. Onycholysis associated with paclitaxel. Cutis 2003;71(3):229-32.

Chen GY, Chen YH, Hsu MM, Tsao CJ, Chen WC. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol 2001;145(3):521-2. http://dx.doi.org/10.1046/j.1365-2133.2001.04391.x

Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinibinduced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 2006;72(1):63-4. http://dx.doi.org/10.4103/0378-6323.19727

Ghoshal UC, Saha J, Ghoshal U, Ray BK, Santra A, Naik S et al. Pigmented nails and Strongyloides stercoralis infestation causing clinical worsening in a patient treated for immunoproliferative small intestinal disease: two unusual observations. J Diarrhoeal Dis Res 1999;17(1):43-5.

Modesto dos Santos V, Sugai TA, Cezar BF, Vasconcellos de Rezende AC. Transverse leukonychia: a case report. Wets Afr J Med 2005;24(2):181-2.

Miyoshi I, Kubola T, Taguchi H. Beaus's lines after chemotherapy for ALL. Intern Med 2007;46(1):61. http://dx.doi.org/10.2169/internalmedicine.46.6095

Reissing A, Hengst U, Kroegel C. Beau's lines and chemotherapy. Med Klin (Munich) 2001;96(2):114-5. http://dx.doi.org/10.1007/PL00002178

Cuétara MS, Alhambra A, Moreno JM, Postigo C, Moragues MD, Pontón J et al. Invasive aspergillosis due to subungual onychomycosis during treatment for non-Hodgkin lymphoma. Br J Dermatol 2006;154(6):1200-2. http://dx.doi.org/10.1111/j.1365-2133.2006.07240.x

Devillers C, Vanhooteghem O, Henrijean A, Ramaut M, de la Brassinne M. Subungueal pyogenic granuloma secondary to docetaxel therapy. Clin Exp Dermatol 2009;34(2):251-2. http://dx.doi.org/10.1111/j.1365-2230.2008.02799.x

Hsu KF, Yang MH, Yu JC. Chemotherapy-induced diffuse melanonychia. Acta Clin Belg 2008;63(6):427.

Saraceno R, Teoli M, Chimenti S. Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. Clin Ther 2008;30(7):1324-9. http://dx.doi.org/10.1016/S0149-2918(08)80057-4

Montero A, Hervás A, Morera R, Sancho S, Córdoba S, Corona JA et al. Control de sintomas crônicos. Efects secundários del tratamiento con radioterapia y quimioterapia. Oncologia (Barc.) 2005;28(3):41-50. http://dx.doi.org/10.4321/S0378-48352005000300008